The Advent of Biosimilars in Oncology: Planning Proactively for Change

Christina Corridon


A Panel Discussion with OBR, ZS and Industry Experts on the Changing Roles of Payers, Providers and Manufacturers

With several oncology biosimilars expected to hit the U.S. market in the next few years, pharmaceutical drug manufacturers need clear insight into stakeholder perceptions and key drivers of adoption in order to thrive in a crowded and complex marketplace.

During this webinar, ZS and industry experts will discuss the following:

  • Current market knowledge and perceptions of biosimilars in therapeutic oncology
  • Experience with existing biosimilars
  • Anticipated adoption of therapeutic biosimilars by physicians, payers and pharmacy directors
  • Drivers and barriers to adoption

Contact us for more insights from ZS’s 2017 Biosimilar Adoption Study.

Access Content

Watch the Replay


Christina Corridon
Christina Corridon is a Associate Principal in the Boston office and a leader in the ZS Oncology Practice. She has over a decade experience working in the pharmaceutical and biotech industries, with specific expertise in oncology and biosimilars. During her consulting career she has worked on US and global projects spanning commercialization strategy including launch strategy and planning, go-to market strategy, commercial models, marketing strategy and brand planning. Christina has an MPH in Health Policy and Management from the UCLA Fielding School of Public Health and an MBA from the Stern School of Business at New York University focused in Marketing. Christina completed her BA at Cornell University.